Business
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.
About this update from Vanda Pharmaceuticals Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motion","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026","length":140,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":416,"olType":false},{"type":"text","content":"WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.","length":203,"tagName":"p"},{"type":"image","alt":"Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":260,"url":"https://media.zenfs.com/en/prnewswire.com/743d2f4492e0b465012535111f8b6bc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t6bNuh3kAr03Rxr6Kla3dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/743d2f4492e0b465012535111f8b6bc6","width":400,"height":260}},"href":"https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""2025 showed strong momentum at Vanda, led by Fanapt, with net product sales up 24% to $117.3 million, driven by a 28% rise in total prescriptions and 149% surge in new-to-brand prescriptions - reflecting accelerating growth in schizophrenia and bipolar I disorder. We await the FDA decision on the Bysanti (milsaperidone) NDA by the February 21, 2026 PDUFA date, which would expand our psychiatry franchise in the global antipsychotic category. This category had a total addressable market estimated at approximately $20 billion in 2025," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.","length":645,"tagNa...